FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

14 letters match. Newest first.

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Sciarra Aeromed, Inc.

    Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.

    High risk
  3. Neogen Corporation

    FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.

    High risk
  4. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  5. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  6. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk
  7. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk
  8. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  9. Fareva Amboise

    FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.

    High risk
  10. Wizcure Pharmaa Private Limited

    FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.

    High risk
  11. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  12. Par Health USA, LLC & Endo USA, Inc.

    FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

    High risk
  13. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  14. Thrive Health and Wellness, LLC dba Thrive Health Solutions

    FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.

    High risk